UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 1, 2012, Pages 96-102

  Wang, Y H ^a   Trucksis, M ^a   McElwee, J J ^a   Wong, P H ^a   MacIolek, C ^a   Thompson, C D ^a   Prueksaritanont, T ^a   Garrett, G C ^a   Declercq, R ^a   Vets, E ^b   Willson, K J ^a   Smith, R C ^a   Klappenbach, J A ^a   Opiteck, G J ^a   Tsou, J A ^a   Gibson, C ^a   Laethem, T ^a   Panorchan, P ^a   Iwamoto, M ^a   Shaw, P M ^a   Wagner, J A ^a   Harrelson, J C ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b SGS Life Science Services   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2 ANTAGONIST; GLUCURONIDE; MK 7246; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; GENE; GENETIC POLYMORPHISM; GENOTYPE; GLUCURONOSYLTRANSFERASE GENE; HUMAN; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CARBOLINES; DOUBLE-BLIND METHOD; DRUG MONITORING; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HALF-LIFE; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ANTIGEN, T-CELL;

EID: 84862622198     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.20     Document Type: Article

References (18)

1. Gallant, M. et al. Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg. Med. Chem. Lett. 21, 288-293 (2011).
2. Gervais, F.G. et al. Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist. Mol. Pharmacol. 79, 69-76 (2011).
3. Maruo, Y., Iwai, M., Mori, A., Sato, H. & Takeuchi, Y. Polymorphism of UDP-glucuronosyltransferase and drug metabolism. Curr. Drug Metab. 6, 91-99 (2005).
4. Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K. & Kamataki, T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol. 9, 845-847 (1998).
5. Ando, Y., Ueoka, H., Sugiyama, T., Ichiki, M., Shimokata, K. & Hasegawa, Y. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther. Drug Monit. 24, 111-116 (2002).
6. Iyer, L. et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47 (2002).
7. Kwara, A. et al. Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J. Clin. Pharmacol. 49, 1079-1090 (2009).
8. He, X. et al. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br. J. Clin. Pharmacol. 68, 721-730 (2009).
9. Turgeon, D., Carrier, J.S., Chouinard, S. & Bélanger, A. Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab. Dispos. 31, 670-676 (2003).
10. Ohno, S. & Nakajin, S. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 37, 32-40 (2009).
11. Wilson, W. 3rd et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 84, 707-714 (2004).
12. Park, J. et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol. Biomarkers Prev. 15, 1473-1478 (2006).
13. J akobsson, J. et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J. Clin. Endocrinol. Metab. 91, 687-693 (2006).
14. Terakura, S. et al. A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br. J. Haematol. 129, 221-228 (2005).
15. Schulze, J.J., Lundmark, J., Garle, M., Skilving, I., Ekström, L. & Rane, A. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J. Clin. Endocrinol. Metab. 93, 2500-2506 (2008).
16. J uul, A. et al. A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys. J. Clin. Endocrinol. Metab. 94, 1005-1011 (2009).
17. Balliet, R.M., Chen, G., Gallagher, C.J., Dellinger, R.W., Sun, D. & Lazarus, P. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res. 69, 2981-2989 (2009).
18. Williams, J.A. et al. Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 32, 1201-1208 (2004).